StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)

Close on Nov 16, 2026Market cap $1.56BP/E –Yield –

Recursion Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Recursion Pharmaceuticals's total debt was $14.20M at Jun 30, 2026. For fiscal 2025 it was $18.66M, down 32.0% from the year before. The highest annual figure on record is $27.45M in fiscal 2024.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.66M-32.0%
FY2024Dec 31, 2024$27.45M+2303.4%
FY2023Dec 31, 2023$1.14M+113.1%
FY2022Dec 31, 2022$536.00K-15.3%
FY2021Dec 31, 2021$633.00K-94.5%
FY2020Dec 31, 2020$11.41M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.20M-38.1%
Q1 FY2026Mar 31, 2026$16.45M-34.3%
Q4 FY2025Dec 31, 2025$18.66M-32.0%
Q3 FY2025Sep 30, 2025$20.82M-27.5%
Q2 FY2025Jun 30, 2025$22.95M-26.0%
Q1 FY2025Mar 31, 2025$25.03M+2237.3%
Q4 FY2024Dec 31, 2024$27.45M+2303.4%
Q3 FY2024Sep 30, 2024$28.73M+2451.4%
Q2 FY2024Jun 30, 2024$31.03M+2586.6%
Q1 FY2024Mar 31, 2024$1.07M-9.2%
Q4 FY2023Dec 31, 2023$1.14M+113.1%
Q3 FY2023Sep 30, 2023$1.13M+100.7%
Q2 FY2023Jun 30, 2023$1.16M+97.1%
Q1 FY2023Mar 31, 2023$1.18M+93.3%
Q4 FY2022Dec 31, 2022$536.00K-15.3%
Q3 FY2022Sep 30, 2022$561.00K-14.5%
Q2 FY2022Jun 30, 2022$586.00K-93.8%
Q1 FY2022Mar 31, 2022$610.00K-94.1%
Q4 FY2021Dec 31, 2021$633.00K-94.5%
Q3 FY2021Sep 30, 2021$656.00K–
Q2 FY2021Jun 30, 2021$9.42M–
Q1 FY2021Mar 31, 2021$10.34M–
Q4 FY2020Dec 31, 2020$11.41M–

More Recursion Pharmaceuticals figures

See a number that looks wrong?